Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BMS-906024 |
Synonyms | |
Therapy Description |
BMS-906024 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (PMID: 28978720). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-906024 | AL 101|AL101|AL-101 | NOTCH Inhibitor (Pan) 5 | BMS-906024 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (PMID: 28978720). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | lung non-small cell carcinoma | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of non-small cell lung carcinoma xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | neuroblastoma | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of neuroblastoma xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | ovarian carcinoma | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of ovarian carcinoma xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | pancreatic carcinoma | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of pancreatic carcinoma xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | glioblastoma | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of glioblastoma xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | triple-receptor negative breast cancer | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of triple-negative breast cancer xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | colon carcinoma | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of colon carcinoma xenografts (PMID: 26005526). | 26005526 |
Unknown unknown | Her2-receptor positive breast cancer | not applicable | BMS-906024 | Preclinical | Actionable | In a preclinical study, the pan-Notch inhibitor, BMS-906024, inhibited growth of ERBB2 (HER2)-positive breast cancer xenografts (PMID: 26005526). | 26005526 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 1 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | 1 |
NCT01363817 | Phase I | Dexamethasone BMS-906024 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Completed | USA | 2 |
NCT04461600 | Phase II | BMS-906024 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY) | Recruiting | USA | 1 |
NCT03691207 | Phase II | BMS-906024 | A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY) | Recruiting | USA | CAN | 4 |